{"hands_on_practices": [{"introduction": "A cornerstone of variant interpretation is assessing a variant's frequency in the general population. For rare Mendelian disorders, a variant that is too common is unlikely to be pathogenic. This exercise guides you through the fundamental process of deriving a maximum credible allele frequency threshold from first principles, a key skill for applying the ACMG/AMP Benign Stand-alone (BA1) criterion. By working through the relationship between disease prevalence ($K$), penetrance ($\\pi$), and genetic heterogeneity ($h$), you will build a quantitative intuition for why population data provides such powerful evidence in variant classification [@problem_id:4323846].", "problem": "A team is curating evidence for the Benign Stand-alone (BA1) criterion from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) for an autosomal dominant disorder. They seek to derive a gene- and variant-specific population allele frequency threshold above which a variant is considered too frequent to be causative for the disorder under scientifically defensible assumptions.\n\nUse the following fundamental bases:\n\n- Under Hardy–Weinberg equilibrium and the rare-allele approximation, an autosomal dominant pathogenic variant with allele frequency $p$ has a heterozygote genotype frequency approximately $2p$, and the homozygote genotype frequency approximately $p^2$, with $p^2$ negligible compared to $2p$ for $p \\ll 1$.\n- Disease prevalence $K$ is the proportion of affected individuals in the population, and penetrance $\\pi$ is the probability that a carrier of the pathogenic genotype expresses the disease phenotype.\n- Genetic heterogeneity can be summarized by a factor $h \\in (0,1]$ that upper-bounds the fraction of all disease cases attributable to the single variant under consideration (that is, at most a fraction $h$ of all cases is due to this variant).\n\nStarting from these bases and no others, derive an analytic expression for the maximum credible population allele frequency threshold $f_{\\max}$ for a single autosomal dominant variant, expressed in terms of $K$, $\\pi$, and $h$, such that any observed general-population allele frequency $f$ greater than $f_{\\max}$ is incompatible with the variant explaining more than an $h$ fraction of disease cases at penetrance $\\pi$. Then, evaluate this threshold for the disorder with prevalence $K=1/1000$, penetrance $\\pi=0.5$, and heterogeneity factor $h=0.1$. Finally, compare the computed threshold to an observed allele frequency $f=0.01$ and determine whether the BA1 criterion should be met (interpret “too frequent for pathogenicity” as meeting BA1).\n\nAnswer specification:\n- Provide the threshold as a decimal in scientific notation, rounded to two significant figures.\n- Report your final answer as a two-entry row in the form $\\begin{pmatrix} f_{\\max}  I \\end{pmatrix}$, where $I$ is a binary indicator equal to $1$ if $f$ is too frequent for pathogenicity under the stated assumptions and $0$ otherwise.\n- Do not include any units or percentage signs in the final answer.", "solution": "The problem requires the derivation of a maximum credible population allele frequency, $f_{\\max}$, for a rare autosomal dominant variant, and its application to a specific scenario to determine if the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) Benign Stand-alone (BA1) criterion is met.\n\nLet $p$ be the allele frequency of the variant in the general population. According to the problem statement, for an autosomal dominant disorder under the rare-allele assumption ($p \\ll 1$) and Hardy-Weinberg equilibrium, the frequency of carrier genotypes is dominated by heterozygotes. The frequency of heterozygotes is given as approximately $2p$. The frequency of homozygous individuals, approximately $p^2$, is considered negligible. Therefore, the total frequency of individuals carrying at least one copy of the pathogenic variant is approximately $2p$.\n\nThe penetrance, $\\pi$, represents the conditional probability that a carrier will express the disease phenotype. The prevalence of the disease attributable specifically to this variant, which we denote as $K_{\\text{variant}}$, is the product of the carrier frequency and the penetrance:\n$$ K_{\\text{variant}} \\approx (2p) \\pi $$\n\nThe total prevalence of the disorder from all causes is given as $K$. The genetic heterogeneity factor, $h$, is defined as the maximum fraction of all disease cases that can be attributed to the single variant under consideration. This establishes a critical inequality: the prevalence due to our specific variant cannot exceed a fraction $h$ of the total disease prevalence. Mathematically, this is expressed as:\n$$ K_{\\text{variant}} \\le h K $$\n\nBy substituting the expression for $K_{\\text{variant}}$ into this inequality, we obtain a constraint on the allele frequency $p$:\n$$ 2p\\pi \\le hK $$\n\nThe maximum credible population allele frequency, $f_{\\max}$, is the allele frequency at the boundary of this constraint, where the equality holds. This represents the upper limit on the allele frequency that is still compatible with the variant being a cause for the disorder under the given assumptions. Any observed allele frequency greater than $f_{\\max}$ would violate the condition. We set $p = f_{\\max}$ and solve the equality:\n$$ 2f_{\\max}\\pi = hK $$\n\nSolving for $f_{\\max}$ yields the desired analytic expression:\n$$ f_{\\max} = \\frac{hK}{2\\pi} $$\n\nThis formula provides the maximum allele frequency consistent with a variant causing up to a fraction $h$ of a disease with total prevalence $K$ and penetrance $\\pi$.\n\nNext, we evaluate this threshold for the specified parameters:\n- Disease prevalence, $K = 1/1000 = 0.001 = 10^{-3}$\n- Penetrance, $\\pi = 0.5$\n- Genetic heterogeneity factor, $h = 0.1 = 10^{-1}$\n\nSubstituting these values into the derived expression for $f_{\\max}$:\n$$ f_{\\max} = \\frac{(0.1) \\times (0.001)}{2 \\times (0.5)} = \\frac{10^{-1} \\times 10^{-3}}{1} = 10^{-4} $$\n\nThe value of the threshold is $f_{\\max} = 0.0001$. As per the problem's instruction for the final answer, this must be expressed in scientific notation rounded to two significant figures, which is $1.0 \\times 10^{-4}$.\n\nFinally, we must compare this calculated threshold to the observed allele frequency, given as $f = 0.01$. The problem states that the BA1 criterion is met if the observed frequency is \"too frequent for pathogenicity\", which is interpreted as $f > f_{\\max}$.\n\nWe compare the values:\n$$ f = 0.01 = 10^{-2} $$\n$$ f_{\\max} = 0.0001 = 10^{-4} $$\n\nSince $10^{-2} > 10^{-4}$, the observed frequency $f$ is indeed greater than the maximum credible frequency $f_{\\max}$. This implies that the observed allele frequency is incompatible with the variant being pathogenic under the specified model of prevalence, penetrance, and heterogeneity. Therefore, the variant is considered \"too frequent for pathogenicity,\" and the BA1 criterion is met. The binary indicator $I$ is thus equal to $1$.\n\nThe final answer requires a two-entry row matrix containing the calculated threshold $f_{\\max}$ and the indicator $I$.\nThe threshold is $1.0 \\times 10^{-4}$ and the indicator is $1$.", "answer": "$$\\boxed{\\begin{pmatrix} 1.0 \\times 10^{-4}  1 \\end{pmatrix}}$$", "id": "4323846"}, {"introduction": "Case-control studies provide critical evidence for pathogenicity, but translating their statistical outputs into the ACMG/AMP framework requires careful consideration. This practice tackles the real-world challenge of interpreting a published odds ratio ($OR$) and its confidence interval to derive a Bayes factor for the Pathogenic Strong (PS4) criterion. You will learn why a conservative approach—using the lower bound of the confidence interval—is essential for rigorously evaluating evidence and avoiding overconfidence in the face of statistical uncertainty [@problem_id:4323775].", "problem": "A missense variant in a disease-associated gene has been evaluated in a case–control study. The study reports an odds ratio $OR = 4.0$ for carriers among cases versus controls, with a $0.95$ confidence interval $[2.0, 8.0]$. Using a Bayesian framework for clinical variant classification, begin from Bayes’ theorem and the definition of a Bayes factor, and derive a conservative Bayes factor to be used for American College of Medical Genetics and Genomics (ACMG) evidence calibration of Pathogenic Strong criterion $4$ (PS4). Explicitly justify the choice of which quantity from the reported statistics should be taken as the Bayes factor in the absence of raw counts. Then, compare the derived Bayes factor to the standard Bayesian calibration thresholds for ACMG evidence strengths, where a Supporting-strength evidence corresponds to approximately $BF_{\\text{supporting}} \\approx 2.08$ and a Moderate-strength evidence corresponds to approximately $BF_{\\text{moderate}} \\approx 4.33$. Determine whether PS4 at Supporting or Moderate strength is appropriate given the reported data and the conservative approach. Provide the Bayes factor as your final answer. No rounding is required. The Bayes factor is dimensionless and should be reported without units.", "solution": "The problem requires the derivation of a conservative Bayes factor ($BF$) from a reported odds ratio ($OR$) and its confidence interval, for the purpose of calibrating evidence strength under the American College of Medical Genetics and Genomics (ACMG) framework for variant classification.\n\nFirst, we begin with the fundamentals of Bayesian inference. Bayes' theorem, expressed in terms of odds, relates the posterior odds of a hypothesis to its prior odds and the Bayes factor. Let $H_1$ be the hypothesis that the genetic variant is pathogenic (i.e., associated with the disease), and $H_0$ be the null hypothesis that the variant is benign (not associated with the disease). Let $D$ represent the observed data from the case-control study. Bayes' theorem in odds form is:\n$$ \\frac{P(H_1|D)}{P(H_0|D)} = \\frac{P(D|H_1)}{P(D|H_0)} \\times \\frac{P(H_1)}{P(H_0)} $$\nThis equation can be written as:\n$$ \\text{Posterior Odds} = \\text{Bayes Factor} \\times \\text{Prior Odds} $$\nThe Bayes factor ($BF$) is defined as the ratio of the likelihood of observing the data given the alternative hypothesis ($H_1$) to the likelihood of observing the data given the null hypothesis ($H_0$):\n$$ BF = \\frac{P(D|H_1)}{P(D|H_0)} $$\nThe $BF$ quantifies the strength of evidence provided by the data $D$ in favor of $H_1$ over $H_0$.\n\nThe data provided are from a case-control study, summarized by an odds ratio, $OR = 4.0$, with a $0.95$ confidence interval ($CI$) of $[2.0, 8.0]$. The odds ratio is the primary statistic used to quantify the association between an exposure (carrying the variant) and an outcome (the disease). In the context of genomic variant classification, particularly for the ACMG Pathogenic Strong criterion $4$ (PS4), the strength of evidence from a case-control study can be mapped to a Bayes factor.\n\nWhile the formal calculation of a Bayes factor from raw case-control data involves integrating the likelihood function over prior distributions for the odds ratio, a common and pragmatic approach, especially when only summary statistics are available, is to use the odds ratio itself as an approximation of the Bayes factor. This is because the $OR$ represents the factor by which the odds of having the disease are increased for a carrier of the variant, which is conceptually equivalent to the strength of evidence provided by the observation of a single carrier in the case population.\n\nThe problem specified that a *conservative* Bayes factor must be derived. The point estimate of the odds ratio, $OR = 4.0$, represents the most likely value based on the sample data, but it is subject to statistical uncertainty. The $0.95$ confidence interval $[2.0, 8.0]$ provides a range of plausible values for the true odds ratio. A conservative approach mandates that we should not overstate the strength of evidence. Therefore, instead of using the point estimate ($4.0$), which could be an overestimate due to random sampling effects, we should use the lower bound of the confidence interval.\n\nThe choice of the lower bound of the $CI$ is justified as it represents a value for the evidentiary strength for which we have a high degree of confidence it is not an overestimate. Using $BF = 2.0$ ensures that we are accounting for the statistical uncertainty and basing our classification decision on a level of evidence that is highly likely to be met or exceeded by the true effect. This practice is consistent with recommendations from expert panels, such as the ClinGen Sequence Variant Interpretation (SVI) working group, for applying evidence from case-control studies.\n\nThus, the conservative Bayes factor to be used for ACMG evidence calibration is derived from the lower bound of the $0.95$ confidence interval for the odds ratio.\nGiven: $0.95$ CI for $OR$ is $[2.0, 8.0]$.\nThe conservative Bayes factor is therefore:\n$$ BF_{\\text{cons}} = 2.0 $$\n\nNext, we must compare this derived Bayes factor to the standard calibrated thresholds for ACMG evidence strengths. The problem provides these thresholds:\n- Supporting-strength evidence: $BF_{\\text{supporting}} \\approx 2.08$\n- Moderate-strength evidence: $BF_{\\text{moderate}} \\approx 4.33$\n\nOur derived conservative Bayes factor is $BF_{\\text{cons}} = 2.0$.\nComparing this value to the thresholds:\n$BF_{\\text{cons}} = 2.0  BF_{\\text{supporting}} \\approx 2.08$\n$BF_{\\text{cons}} = 2.0 \\ll BF_{\\text{moderate}} \\approx 4.33$\n\nThe derived conservative Bayes factor of $2.0$ is slightly below the threshold required for Supporting-strength evidence ($2.08$). It is substantially below the threshold for Moderate-strength evidence. Therefore, based on a strict and conservative application of the Bayesian calibration, the evidence from this case-control study does not meet the quantitative standard to apply the PS4 criterion at Supporting strength. It is certainly not appropriate to apply it at Moderate strength. The final answer requested is the value of the derived Bayes factor.", "answer": "$$\\boxed{2.0}$$", "id": "4323775"}, {"introduction": "The final step in variant classification involves synthesizing multiple, independent lines of evidence into a coherent judgment. This exercise serves as a capstone, demonstrating how to use the formal Bayesian framework to combine various evidence codes, represented as likelihood ratios ($LR$), with a prior belief about a variant's pathogenicity. By calculating the posterior odds and probability, you will see precisely how evidence of varying strengths—strong, moderate, and supporting—quantitatively updates our assessment and leads to a final classification into one of the five standard tiers [@problem_id:4323819].", "problem": "A Bayesian reinterpretation of variant classification integrates evidentiary criteria from the American College of Medical Genetics and Genomics (ACMG) as likelihood ratios, combining them with a baseline prior on pathogenicity to yield a posterior probability. Start from Bayes theorem and the definition of odds, where the odds are $O = \\frac{P}{1-P}$ for a probability $P$, and use the fact that independent evidentiary items multiply as likelihood ratios. For a missense variant under evaluation, suppose the prior odds of pathogenicity are $O_{prior} = \\frac{1}{10}$ and three evidentiary items contribute likelihood ratios: a functional assay meeting a strong criterion contributes $18.7$, a location-based criterion meeting a moderate criterion contributes $4.3$, and a computational prediction meeting a supporting criterion contributes $2.1$. Assume the evidentiary likelihood ratios are independent and applicable for this variant.\n\nUsing first principles, derive the expression needed to compute the posterior odds $O_{post}$ and posterior probability $P_{post}$ for pathogenicity from $O_{prior}$ and the likelihood ratios. Then evaluate $O_{post}$ and $P_{post}$ numerically. Round $O_{post}$ to four significant figures and $P_{post}$ to five significant figures.\n\nFinally, determine the implied classification tier using the following posterior probability thresholds, and report the tier as a numeric code:\n- Pathogenic: $P_{post} \\ge 0.99$ (code $5$).\n- Likely Pathogenic: $0.90 \\le P_{post}  0.99$ (code $4$).\n- Variant of Uncertain Significance: $0.10  P_{post}  0.90$ (code $3$).\n- Likely Benign: $0.001  P_{post} \\le 0.10$ (code $2$).\n- Benign: $P_{post} \\le 0.001$ (code $1$).\n\nExpress your final answer as three values: $O_{post}$, $P_{post}$, and the classification code, in that order. Do not include any units. If you use percentages at any point, convert them to decimal form in the final values.", "solution": "The problem requires the application of Bayes' theorem in odds form to combine multiple independent lines of evidence and derive a posterior probability of pathogenicity, which is then used to classify a genetic variant.\n\n**1. Derivation of Formulas**\n\nFirst, we recall the odds form of Bayes' theorem. The posterior odds of a hypothesis ($O_{post}$) are equal to the prior odds ($O_{prior}$) multiplied by the likelihood ratio ($LR$) of the evidence:\n$$ O_{post} = O_{prior} \\times LR $$\nWhen there are multiple independent lines of evidence ($E_1, E_2, ..., E_n$), the total likelihood ratio ($LR_{total}$) is the product of the individual likelihood ratios ($LR_i$):\n$$ LR_{total} = \\prod_{i=1}^{n} LR_i $$\nTherefore, the posterior odds can be calculated as:\n$$ O_{post} = O_{prior} \\times \\prod_{i=1}^{n} LR_i $$\nOnce the posterior odds are known, the posterior probability ($P_{post}$) can be derived from the definition of odds, $O = P / (1 - P)$:\n$$ P_{post} = \\frac{O_{post}}{1 + O_{post}} $$\nThese are the expressions needed to solve the problem.\n\n**2. Numerical Evaluation**\n\nWe are given the following values:\n- Prior odds: $O_{prior} = \\frac{1}{10} = 0.1$\n- Likelihood ratios: $LR_1 = 18.7$ (strong), $LR_2 = 4.3$ (moderate), $LR_3 = 2.1$ (supporting).\n\nFirst, we calculate the posterior odds by multiplying the prior odds by the product of the three likelihood ratios:\n$$ O_{post} = 0.1 \\times 18.7 \\times 4.3 \\times 2.1 = 16.8861 $$\nRounding to four significant figures as requested, we get:\n$$ O_{post} \\approx 16.89 $$\nNext, we use this posterior odds value to calculate the posterior probability. For better accuracy, we use the unrounded value of $O_{post}$:\n$$ P_{post} = \\frac{16.8861}{1 + 16.8861} = \\frac{16.8861}{17.8861} \\approx 0.944085... $$\nRounding to five significant figures as requested, we get:\n$$ P_{post} \\approx 0.94409 $$\n\n**3. Classification**\n\nFinally, we classify the variant by comparing the posterior probability $P_{post} \\approx 0.94409$ to the provided classification thresholds. The thresholds are:\n- Pathogenic: $P_{post} \\ge 0.99$ (code $5$)\n- Likely Pathogenic: $0.90 \\le P_{post}  0.99$ (code $4$)\n- Variant of Uncertain Significance: $0.10  P_{post}  0.90$ (code $3$)\n- Likely Benign: $0.001  P_{post} \\le 0.10$ (code $2$)\n- Benign: $P_{post} \\le 0.001$ (code $1$)\n\nOur calculated posterior probability $P_{post} \\approx 0.94409$ satisfies the condition $0.90 \\le 0.94409  0.99$. Therefore, the variant is classified as **Likely Pathogenic**, which corresponds to the numeric code **4**.\n\nThe final answer consists of the posterior odds, posterior probability, and the classification code.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n16.89  0.94409  4\n\\end{pmatrix}\n}\n$$", "id": "4323819"}]}